Anti-CD20 monoclonal antibodies: reviewing a revolution

Anti-CD20 monoclonal antibodies: reviewing a revolution

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment...

Full description

Bibliographic Details
Main Authors:	J. M. L. Casan, J. Wong, M. J. Northcott, S. Opat
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	monoclonal antibody cd20 rituximab obinutuzumab immunotherapy lymphoma
Online Access:	http://dx.doi.org/10.1080/21645515.2018.1508624

Similar Items

Disseminated Enteroviral Infection Associated with Obinutuzumab
by: Claire Dendle, et al.
Published: (2015-09-01)

New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
by: Biswanath Basu, et al.
Published: (2022-02-01)

Production and Characterization of New Anti-Human CD20 Monoclonal Antibody
by: Mahdi Fasihi-Ramandi, et al.
Published: (2015-10-01)

Monoclonal anti-CD20 antibodies in lymphomas therapy during the COVID-19 pandemic: pro and contra
by: K. A. Sychevskaya, et al.
Published: (2022-04-01)

Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis
by: Michael Constantinides, et al.
Published: (2023-02-01)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
by: Ma B, et al.
Published: (2017-04-01)

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
by: Shlomo Elias, et al.
Published: (2018-06-01)

An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab
by: Tali Shafat, et al.
Published: (2024-02-01)

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
by: Timothy M. Pierpont, et al.
Published: (2018-06-01)

A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature
by: Noa Bigman-Peer, et al.
Published: (2022-08-01)

Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells
by: Agnieszka Dabkowska, et al.
Published: (2024-04-01)

Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis
by: Sabine Tacke, et al.
Published: (2022-03-01)

The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
by: Alicja Kuźniewska, et al.
Published: (2023-12-01)

Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates
by: Petros Ioannou, et al.
Published: (2023-03-01)

Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment
by: Letizia Polito, et al.
Published: (2013-10-01)

The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma
by: K D Kaplanov, et al.
Published: (2014-06-01)

Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases
by: Pejčić Ivica, et al.
Published: (2009-01-01)

Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131
by: Akinkunmi Ganiyu Akanji, et al.
Published: (2005-10-01)

An update on newer monoclonal antibodies in lymphoma therapy
by: Subhashini Archana Kadavakolan, et al.
Published: (2016-01-01)

Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?
by: Umut Yılmaz, et al.
Published: (2024-01-01)

Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
by: Onishi A, et al.
Published: (2023-01-01)

In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies
by: Aleksandra Urban, et al.
Published: (2022-03-01)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
by: Naoki Wada, et al.
Published: (2009-10-01)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
by: Jennifer R. Blase, et al.
Published: (2022-04-01)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
by: Suheil Albert Atallah-Yunes, et al.
Published: (2022-01-01)

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
by: Despina Fotiou, et al.
Published: (2022-01-01)

Construction and Characterization of 1F5 Chimeric Anti-CD20 Monoclonal Antibodies: An Efficient Splicing by Overlap Extension-polymerase Chain Reaction Technique
by: Fatemeh Khademi, et al.
Published: (2021-04-01)

Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma
by: Nutthanit Thumrongsiri, et al.
Published: (2022-06-01)

FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy
by: Beata Pyrzynska, et al.
Published: (2018-05-01)

The Role of Rituximab in Lymphomas
by: Bertrand Coiffier
Published: (2002-01-01)

Disseminated Infections with Talaromyces marneffei in Non-AIDS Patients Given Monoclonal Antibodies against CD20 and Kinase Inhibitors
by: Jasper F.W. Chan, et al.
Published: (2015-07-01)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
by: Sonia Boyer-Suavet, et al.
Published: (2020-01-01)

CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
by: Malgorzata Bobrowicz, et al.
Published: (2020-12-01)

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies
by: Ester Fagnano, et al.
Published: (2023-10-01)

Real world safety of CT-P10 (anti-CD 20 monoclonal antibodies biosimilar) in rheumatic and autoimmune diseases
by: Wanruchada Katchamart, et al.
Published: (2022-11-01)

Enhancement of effector functions of anti-CD20 monoclonal antibody by increased afucosylation in CHO cell line through cell culture medium optimization
by: Bala Reddy Bheemareddy, et al.
Published: (2022-10-01)

Refractory pemphigus vulgaris successfully treated with ofatumumab
by: Daniel M. Klufas, MD, et al.
Published: (2020-08-01)

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
by: Luan C, et al.
Published: (2019-08-01)

Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases
by: Carlos Martínez-Chinchilla, et al.
Published: (2022-04-01)

Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T
by: Adam M. Kase, et al.
Published: (2022-04-01)